Crinetics Pharmaceuticals, Inc. 8-K

What Happened
Crinetics Pharmaceuticals, Inc. (CRNX) held its annual meeting on June 18, 2026 (live audio webcast) and reported voting results in an 8-K filed June 22, 2026. Approximately 102,030,415 shares were represented, about 97% of outstanding shares. Stockholders elected three Class II directors for three-year terms (expiring 2029), ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.

Key Details

• Total shares represented: 102,030,415 (~97% of outstanding eligible shares).
• Director election votes:
  • Caren Deardorf — For: 73,454,076; Withheld: 23,532,328; Broker non-votes: 5,044,011.
  • Weston Nichols, Ph.D. — For: 90,208,564; Withheld: 6,777,840; Broker non-votes: 5,044,011.
  • Stephanie S. Okey, M.S. — For: 72,225,313; Withheld: 24,761,091; Broker non-votes: 5,044,011.
• Auditor ratification (PricewaterhouseCoopers LLP): For 101,675,974; Against 341,727; Abstentions 12,714.
• Advisory "say-on-pay" vote: For 91,657,992; Against 2,698,538; Abstentions 2,629,874; Broker non-votes: 5,044,011.

Why It Matters
These results confirm board composition and governance continuity through 2029 for investors, and ratification of PwC maintains continuity in external audit oversight for fiscal 2026. The strong advisory vote for executive compensation signals majority shareholder support for pay practices (note: advisory/say‑on‑pay votes are non‑binding). High participation (≈97%) and the presence of broker non-votes on some items are notable for interpreting margins on contested director votes.